United Therapeutics

Summary

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

History

United Therapeutics was founded in 1996 by Martine Rothblatt, an American lawyer, author, and entrepreneur, who created Sirius XM. In 1994, Rothblatt's young daughter was diagnosed with a fatal orphan disease, pulmonary arterial hypertension . Rothblatt sold her telecom stock and started the PPH Cure Foundation to fund PAH research.In 2002, the U.S. Food and Drug Administration approved United Therapeutics' drug Remodulin, a prostacyclin vasodilator used to treat PAH. Remodulin provided PAH patients with an alternative to GlaxoSmithKline's Flolan. By 2003, Remodulin annual sales had reached $50 million. By 2010, annual sales were $300 million and United Therapeutics' share price had increased 800 percent from the 1999 initial public offering price.In 2011, United Therapeutics acquired Revivicor, a company focused on developing genetic biotechnology platforms to provide alternative tissue sources for treatment. In 2018, the company acquired SteadyMed, a medical device company developing injectable therapeutic drugs for pulmonary hypertension. Other acquisitions include SynQuest in 1999 and Cooke Pharma in 2000. United Therapeutics has entered numerous licensing agreements and collaborations with companies such as Eli Lilly and Company, Medtronic, DEKA Research & Development, and the National Cancer Institute. In March 2021, United Therapeutics’ market capitalization was $7.1 billion.On January 7, 2022, a porcine heart provided by United Therapeutics in conjunction with Kiniksa Pharmaceuticals and the University of Maryland Medical Center was used in the first pig-to-human transplant operation. The recipient subsequently passed away on Tuesday, March 8, 2022.

Mission

To focuses on the strength of a balanced, value-creating biotechnology model

Vision

To grow business to be in the top quintile of our peers.

References

https://en.wikipedia.org/wiki/United_Therapeutics

https://in.investing.com/equities/united-therapeutics-corp

https://finance.yahoo.com/quote/UTHR/profile?p=UTHR

https://www.comparably.com/companies/united-therapeutics/mission

https://www.crunchbase.com/organization/united-therapeutics-unither

https://sec.report/CIK/0001082554

https://companiesmarketcap.com/